Tacrine analog octahydroaminoacridine (or octohydroaminoacridine) is an acetylcholinesterase inhibitor and was studied for the treatment of Alzheimer’s disease (AD). Phase II clinical trial was successfully completed, where octahydroaminoacridine significantly improved cognitive function and behavior in patients with mild-to-moderate AD and this effect was dose dependent. Now this drug is involved in phase III clinical trial on the stage of recruiting the patients.